Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
LOS ANGELES, June 08, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (Nasdaq:ITCI) for possible violations of federal securities laws between August 12, 2014 and April 28, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The Complaint states that, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On August 4, 2016, Intra-Cellular’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. When this information was released, Intra-Cellular’s stock price decreased materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
